Group 1 - The cell immunotherapy concept index rose by 1.25%, ranking 6th among concept sectors, with 29 stocks increasing in value [1][2] - Notable gainers included Ruizhi Pharmaceutical with a 20% limit up, Hainan Haiyao at limit up, and Shutaishen, Guanhao Biological, and Fosun Pharma with increases of 15.02%, 8.88%, and 5.23% respectively [1][6] - The sector experienced a net outflow of 266 million yuan, with 20 stocks seeing net inflows, and 8 stocks receiving over 10 million yuan in net inflows, led by Hainan Haiyao with a net inflow of 144 million yuan [2][3] Group 2 - Hainan Haiyao, Anke Bio, and Dongcheng Pharmaceutical had the highest net inflow ratios at 35.56%, 5.52%, and 5.27% respectively [3][4] - The top stocks by net inflow included Hainan Haiyao, Fosun Pharma, Ruizhi Pharmaceutical, and Zhaoyan New Drug, with net inflows of 144 million yuan, 54.52 million yuan, 34.78 million yuan, and 31.86 million yuan respectively [2][3] - Stocks with significant declines included Xue Rong Biological, Saifutian, and Jinchang Protein, with decreases of 4.23%, 2.74%, and 2.61% respectively [1][5]

Group 1: Strategic Focus - The company's strategic focus for 2025 is on overseas markets, which account for approximately 75% of its business, and cornerstone business segments that contribute about 90% of revenue [1] - New business segments primarily target domestic customers, with ongoing efforts to develop overseas markets in molecular business and gene cell therapy [1] Group 2: Market Presence and Operations - The company does not have separate operational entities in Japan and South Korea but has business development efforts in these markets, which have shown promising growth since 2024 [2] - The Slovenia R&D and production base serves global clients, with a core customer base primarily from Europe [2] Group 3: Order and Delivery Insights - The average order delivery cycle ranges from 3 to 18 months, depending on project requirements, with no significant seasonal delivery patterns [2] - Specific data on Q1 2025 orders was not disclosed due to reporting constraints [2] Group 4: Financial Performance and Projections - The revenue from the formulation business declined by 40% in Q1 2025, primarily due to project delivery timing [3] - The company's gross margin is in a recovery phase, with the core business segment of small molecule APIs maintaining a gross margin of approximately 33% in 2024 [3] - The company aims to enhance revenue scale and introduce more high-value projects to optimize product structure and improve operational efficiency for sustained gross margin recovery [3]

重庆博腾制药科技股份有限公司（以下简称"公司"）于 2025 年 5 月 8 日召 开第六届董事会第一次临时会议，审议通过《关于续聘公司高级管理人员的议案》 《关于续聘公司证券事务代表的议案》，同意公司续聘高级管理人员及证券事务 代表事项。具体情况如下： 股票代码：300363 股票简称：博腾股份 公告编号：2025-030号 重庆博腾制药科技股份有限公司 关于续聘高级管理人员及证券事务代表的公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 同意续聘居年丰先生为公司总经理，白银春先生为公司高级副总经理、首席 运营官，陈晖先生为公司副总经理、首席财务官，皮薇女士为公司副总经理、董 事会秘书，朱坡先生、陈琪先生为公司副总经理，汪星星女士为公司证券事务代 表。 上述人员任期均自公司董事会审议通过之日起至第六届董事会届满时止。上 述人员简历见附件。上述人员的任职资格符合《中华人民共和国公司法》《深圳 证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》等法律法规，以及公司《公司章程》等相关规定。 董事会秘书皮薇女士、 ...

股票代码：300363 股票简称：博腾股份 公告编号：2025-031 号 重庆博腾制药科技股份有限公司 第六届监事会第一次临时会议决议公告 根据《公司章程》《监事会议事规则》的相关规定，为保障公司第六届监事 会各项工作的顺利开展，同意选举谭永庆先生为公司第六届监事会主席，任期自 本次监事会审议通过之日起至公司第六届监事会届满时止。 公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆博腾制药科技股份有限公司（以下简称"公司"）第六届监事会第一次 临时会议于 2025 年 5 月 8 日（星期四）以通讯会议方式召开，会议通知已于 2025 年 4 月 29 日通过电子邮件方式送达各位监事。本次会议应参与表决监事人数 3 人，实际参与表决监事人数 3 人，经公司全体监事共同推举，本次会议由监事谭 永庆先生主持。 会议在保证所有监事充分发表意见的前提下，以投票的方式进行表决。会议 召开符合《中华人民共和国公司法》及《公司章程》的规定，所作决议合法有效。 一、 会议审议情况 经与会监事认真审议，以投票表决方式通过以下议案： 1、审议通过《关于选举公司第六届监事会主席的 ...

股票代码：300363 股票简称：博腾股份 公告编号：2025-029 号 重庆博腾制药科技股份有限公司 第六届董事会第一次临时会议决议公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2、审议通过《关于选举第六届董事会各专门委员会成员的议案》； 根据《公司章程》《董事会议事规则》等相关规定，公司第六届董事会下设 审计委员会、提名委员会、薪酬与考核委员会、战略与 ESG 委员会等四个专门 委员会，各专门委员会组成建议如下： 审计委员会：庞金伟（主任委员）、袁林、曹国华 重庆博腾制药科技股份有限公司（以下简称"公司"）第六届董事会第一次 临时会议于 2025 年 5 月 8 日（星期四）以通讯会议方式召开，会议通知已于 2025 年 4 月 29 日通过电子邮件方式送达各位董事。本次会议应参与表决董事人数 7 人，实际参与表决董事人数 7 人。经公司全体董事共同推举，本次会议由董事居 年丰先生主持，公司部分监事、高级管理人员列席会议。 会议召开符合《公司法》及《公司章程》的规定，所作决议合法有效。 一、 会议审议情况 会议在保证所有董事充分发表意见的前提下，以 ...

Group 1: Xiangsheng Medical - The company emphasizes shareholder returns, with a 2024 dividend plan of 10 CNY per 10 shares, totaling 112 million CNY, which accounts for 79.62% of net profit [1] - In 2024, the company plans to invest nearly 80 million CNY in R&D, with 48 new patent authorizations and 5 domestic and 35 international market access licenses [1] - The breast artificial intelligence ultrasound robot is designed for breast cancer screening, integrating ultrasound, robotics, and AI technology for large-scale patient screening [1] - The company is mitigating risks from US tariffs through global market expansion and ODM models, aiming to build a global supply chain and explore emerging markets [1] Group 2: Boteng Co., Ltd. - Despite external uncertainties, the company remains a key supply chain partner for clients, with limited impact from current tariff policies as products fall within the exemption range [2] - The company's gross margin fluctuations are mainly influenced by domestic market conditions and new business losses, while overseas markets and core business margins remain stable [2] - The company has increased production and R&D capabilities through acquisitions and self-construction, with a growing order backlog expected to convert into revenue in 2024 and 2025 [2] - New molecular business is growing rapidly, but the timeline for reaching breakeven is uncertain, with 2025 capital expenditures focused on overseas expansion and upgrading existing capacities [2] Group 3: ST Huatuo - The company focuses on evergreen game categories like SLG and match-3 games, emphasizing innovation and scalability [3] - The company believes that the trend for SLG games is favorable due to ease of operation and strong user retention, although successful teams are limited [3] - The company plans to leverage cost reduction and efficiency improvements to return to traditional advantages and explore overseas markets [3] - The company is optimistic about AI game development, hosting innovation competitions while maintaining a cautious short-term outlook [3]

Group 1: Impact of External Factors - The geopolitical factors, such as the Biosecurity Act, influence clients' strategies, leading them to seek multiple suppliers to manage supply chain risks [1] - Current tariff policies have limited impact on the company, as less than 5% of its revenue comes from direct exports to the U.S., and products fall within the tariff exemption range [2] Group 2: Financial Performance - The company's overall gross margin fluctuates mainly due to domestic market conditions and losses in new business, while overseas market and core business margins remain stable [3] - In Q1 2025, the new molecular business generated approximately CNY 14.19 million in revenue, reflecting a year-on-year growth of about 353% [7] Group 3: Production Capacity and Orders - The company has expanded its production and R&D capabilities through acquisitions and the establishment of new centers, including factories in Hubei and Shanghai [4] - The order conversion cycle typically ranges from 6 to 18 months, with some orders taking 2 to 3 years to convert into revenue [6] Group 4: Future Investments - The capital expenditure for 2025 will focus on overseas expansion, new molecular technology development, and upgrading existing small molecule production capacity [8]

股票代码：300363 股票简称：博腾股份 公告编号：2025-028 号 重庆博腾制药科技股份有限公司 刘佳女士符合《公司法》等法律法规及《公司章程》规定的有关职工代表监 事的任职资格和条件。 公司第五届监事会职工代表监事曾会女士不再担任公司职工代表监事职务， 仍将在公司担任其他职务。截至本公告披露日，曾会女士未直接或间接持有公司 股份，亦不存在应当履行而未履行的承诺事项。公司监事会对曾会女士在担任公 司职工代表监事期间的勤勉尽责表示衷心感谢！ 特此公告。 重庆博腾制药科技股份有限公司监事会 2025 年 4 月 29 日 附件： 关于职工代表大会选举产生第六届监事会职工代表监事 的公告 公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆博腾制药科技股份有限公司（以下简称"公司"）第五届监事会任期已 届满，根据《公司法》《公司章程》等有关规定，公司于 2025 年 4 月 27 日召开 2025 年第二次职工代表大会，选举刘佳女士为公司第六届监事会职工代表监事 （简历见附件）。 根据《公司章程》的规定，监事会由 3 名监事组成，其中职工监事 1 名。本 次选 ...

Core Insights - The global and US innovative drug VC&PE financing amounts are expected to grow by 1.93% and 5.29% respectively in 2024, indicating a recovery in the innovative drug financing environment [1] - The demand for research and development in fields such as peptides and ADCs is strong, leading to an increase in outsourcing needs in these areas [1][2] Macro Perspective - The global innovative drug financing environment is recovering, with significant growth in the demand for innovative research in specific fields like peptides and ADCs, which is expected to enhance the CXO industry's outlook [1] - According to Crunchbase, the VC&PE financing for innovative drugs in 2024 shows positive growth, marking an improvement in the financing environment [1] Micro Perspective - CXO listed companies are seeing a recovery in new orders, with many companies like WuXi AppTec, WuXi Biologics, and others reporting a year-on-year increase of over 20% in new orders [3] - The production capacity of domestic CXO companies is mature, ensuring timely delivery of orders, which is expected to lead to double-digit revenue growth for several companies in 2025 [3] Target Companies - Recommended companies to watch include WuXi AppTec (603259.SH, 02359), WuXi Biologics (02269), WuXi AppTec (02268), Kelun Pharmaceutical (002821.SZ, 06821), and others [4]

Group 1: Financial Performance - In Q1, the small molecule API revenue experienced a high growth of 20%, driven by increased orders from overseas markets signed last year [1] - The gross margin for Q1 was 26.33%, with a year-on-year increase of approximately 10 percentage points [2] - The company aims to maintain a trend of stable or decreasing overall expenses through continuous cost control efforts [2] Group 2: Orders and Market Trends - New orders in Q1 remained at a good level, with backlogged orders still showing growth despite a high base from the previous year [2] - The company observed a slight improvement in overseas customer demand, although the overall improvement remains modest [3] Group 3: Business Strategy and Focus Areas - The company is focusing on high-value markets, clients, and pipelines, particularly in the cardiovascular, renal, and metabolic (CVRM) fields, as well as autoimmune and oncology sectors [4][5] - Capital expenditure plans will primarily revolve around specific technological capabilities and client-triggered investments [5] Group 4: Challenges and Responses - The company is monitoring the impact of changing tariff policies, which currently have limited effect due to the low percentage of direct exports to the U.S. [3] - The gene cell therapy business showed a reduction in losses in Q1, while the small molecule formulation business faced increased losses due to market challenges [2]